GlassScriptPhysician profile
Haris Athar
NPI 1740300938
$9,492.08
in general payments reported to CMS, 2019-2025
15 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $239 · 2021: $400 · 2022: $3,160 · 2023: $3,964 · 2024: $791 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,876 · Food and Beverage: $2,353 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,875.70 |
| Food and Beverage | $2,352.90 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,305.03 | 2019-2025 | Aveir, Assurity, Cardiomems |
| Edwards Lifesciences Corporation | $2,958.53 | 2019-2025 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $349.73 | 2022-2025 | Opsumit, Uptravi |
| Baylis Medical Company INC | $234.35 | 2021 | |
| Cardiva Medical, INC. | $175.42 | 2024-2025 | Cardiva Vascade 6/7f Vcs, Savvywire, Optowire |
| E.R. Squibb & Sons, L.L.C. | $101.30 | 2024-2025 | Camzyos, Coumadin |
| Baxter Healthcare | $77.61 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $70.22 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $43.66 | 2019-2025 | |
| Medtronic Vascular, INC. | $43.46 | 2019-2020 | |
| Amgen INC. | $34.80 | 2025 | Repatha |
| Medtronic, INC. | $31.10 | 2023-2025 | Symplicity G3 |
| Kiniksa Pharmaceuticals International, Plc | $27.94 | 2024 | Arcalyst |
| Pfizer INC. | $27.53 | 2023 | |
| Angiodynamics, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haris Athar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.